Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Lipigon Pharmaceuticals

0,01 SEK

-87,42 %

Mindre end 1K følgere

LPGO

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Oversigt
Finansielt overblik og estimater
Ejerskab
Investorkonsensus
Sammenligne
-87,42 %
-88,07 %
-93,18 %
-88,07 %
-86,90 %
-91,12 %
-98,37 %
-
-99,80 %

Lipigon Pharmaceuticals operates in the pharmaceutical industry. The company specializes in research and development of various drug candidates. The product portfolio is broad and includes drugs for rare diseases. These are primarily treatments for diseases caused by disorders in the body's handling of fats. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in the Nordic market.

Læs mere
Markedsværdi
7,03 mio. SEK
Aktieomsætning
2,18 mio. SEK
Omsætning
10,29 mio.
EBIT %
-248,59 %
P/E
-
Udbytteafkast, %
-
Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
26.3
2026

Årsrapport '25

14.5
2026

Delårsrapport Q1'26

25.8
2026

Delårsrapport Q2'26

Alle
Selskabsmeddelelser
ViserAlle indholdstyper
Selskabsmeddelelsei går

Lipigon Pharmaceuticals presents top-line data from the Phase II clinical trial of Lipisense in patients with elevated blood lipid levels

Lipigon Pharmaceuticals
Pressemeddelelse21.11.2025, 11.19

Redeye: Lipigon (Q3 Review) - Topline Before Year-End

Lipigon Pharmaceuticals
Pressemeddelelse14.10.2025, 20.58

Lipigon Pharmaceuticals reports last patient visit in the three-month follow-up of its Phase II clinical study with Lipisense

Lipigon Pharmaceuticals

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Pressemeddelelse26.8.2025, 12.28

Redeye: Lipigon Q2 2025 - Last Patient In

Lipigon Pharmaceuticals
Selskabsmeddelelse6.7.2025, 07.03

Lipigon Pharmaceuticals Enrolls Last Patient in Phase II Study with Lipisense®

Lipigon Pharmaceuticals
Pressemeddelelse27.5.2025, 06.36

Redeye: Lipigon Q1 2025 - 64.5% Subscription Rate in the Rights Issue

Lipigon Pharmaceuticals
Pressemeddelelse31.3.2025, 06.25

Redeye: Lipigon Q4 2024 - Rights issue funds 2025

Lipigon Pharmaceuticals
Selskabsmeddelelse20.3.2025, 11.15

Lipigon Pharmaceuticals' commercial partner announces positive results from Phase I clinical trial with Lipisense

Lipigon Pharmaceuticals
Pressemeddelelse21.11.2024, 13.12

Redeye: Lipigon Q3 2024 - First Patient Recruited

Lipigon Pharmaceuticals
Selskabsmeddelelse21.11.2024, 09.00

Första patienten doserad i Lipigon Pharmaceuticals kliniska fas II-studie med Lipisense®

Lipigon Pharmaceuticals
Pressemeddelelse18.9.2024, 10.51

Lipigon's development partner Leaderna Therapeutics reports last person treated in ongoing Phase 1 study with Lipisense®

Lipigon Pharmaceuticals
Pressemeddelelse28.8.2024, 05.43

Redeye: Lipigon Q2 2024 - Marea Launched

Lipigon Pharmaceuticals
Selskabsmeddelelse9.7.2024, 12.00

Lipigon Receives Milestone Payment of USD 1 Million from Leaderna for Approval of Phase I Bridging Study

Lipigon Pharmaceuticals
Pressemeddelelse20.6.2024, 06.30

New Publication: The ANGPTL4 Protein May Reduce the Risk of Cardiovascular Disease and Diabetes

Lipigon Pharmaceuticals
Pressemeddelelse29.5.2024, 06.03

Redeye: Lipigon Q1 2024 - Phase II Underway

Lipigon Pharmaceuticals
Pressemeddelelse15.5.2024, 06.28

Lipigon and Leaderna Collaboration on Lipisense® Shows Good Progress

Lipigon Pharmaceuticals
Selskabsmeddelelse14.5.2024, 05.53

Lipigon collaborates with University of Washington on lung damage project

Lipigon Pharmaceuticals
Pressemeddelelse23.2.2024, 07.08

Redeye: Lipigon Q4 2023 - Phase II study approved

Lipigon Pharmaceuticals
Pressemeddelelse7.2.2024, 15.00

The Swedish Medical Products Agency approves Lipigon's phase II study with Lipisense®

Lipigon Pharmaceuticals
Pressemeddelelse12.12.2023, 09.11

Lipisense® progressing to Phase II - what comes next?

Lipigon Pharmaceuticals
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.